Replies to post #132173 on Biotech Values

[genisi]

BLRX was up 34% in TASE on this news:

http://www.globes.co.il/serveen/globes/docview.asp?did=1000718479&fid=1725

If this is an oral HCV protease inhibitor that didn't even enter the clinic, I don't understand the market's reaction at all.